COSMO Pharmaceuticals SA - Asset Resilience Ratio
COSMO Pharmaceuticals SA (COPN) has an Asset Resilience Ratio of 10.92% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read COSMO Pharmaceuticals SA debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how COSMO Pharmaceuticals SA's Asset Resilience Ratio has changed over time. See COSMO Pharmaceuticals SA shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down COSMO Pharmaceuticals SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see COSMO Pharmaceuticals SA stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF66.84 Million | 10.92% |
| Total Liquid Assets | CHF66.84 Million | 10.92% |
Asset Resilience Insights
- Moderate Liquidity: COSMO Pharmaceuticals SA has 10.92% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
COSMO Pharmaceuticals SA Industry Peers by Asset Resilience Ratio
Compare COSMO Pharmaceuticals SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 7.18% |
|
CSPC Pharmaceutical Group Limited
F:CVG |
Drug Manufacturers - General | 4.64% |
|
Aurora Optoelectronics Co Ltd
SHG:600666 |
Drug Manufacturers - General | 5.89% |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281 |
Drug Manufacturers - General | 6.44% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 10.10% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 7.18% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 14.06% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
Annual Asset Resilience Ratio for COSMO Pharmaceuticals SA (2009–2025)
The table below shows the annual Asset Resilience Ratio data for COSMO Pharmaceuticals SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.92% | CHF66.84 Million ≈ $84.51 Million |
CHF612.16 Million ≈ $773.93 Million |
-4.34pp |
| 2024-12-31 | 15.26% | CHF98.67 Million ≈ $124.74 Million |
CHF646.77 Million ≈ $817.69 Million |
-- |
| 2023-12-31 | 0.00% | CHF0.00 ≈ $0.00 |
CHF553.98 Million ≈ $700.38 Million |
-- |
| 2022-12-31 | 7.26% | CHF55.13 Million ≈ $69.70 Million |
CHF759.59 Million ≈ $960.33 Million |
+4.32pp |
| 2021-12-31 | 2.94% | CHF23.65 Million ≈ $29.90 Million |
CHF805.56 Million ≈ $1.02 Billion |
-1.58pp |
| 2020-12-31 | 4.51% | CHF26.91 Million ≈ $34.03 Million |
CHF596.16 Million ≈ $753.71 Million |
-22.46pp |
| 2019-12-31 | 26.97% | CHF157.82 Million ≈ $199.53 Million |
CHF585.16 Million ≈ $739.80 Million |
+4.80pp |
| 2018-12-31 | 22.18% | CHF138.75 Million ≈ $175.41 Million |
CHF625.69 Million ≈ $791.04 Million |
+16.60pp |
| 2017-12-31 | 5.57% | CHF27.76 Million ≈ $35.09 Million |
CHF497.97 Million ≈ $629.57 Million |
-5.44pp |
| 2016-12-31 | 11.01% | CHF48.84 Million ≈ $61.74 Million |
CHF443.47 Million ≈ $560.67 Million |
+0.72pp |
| 2015-12-31 | 10.29% | CHF45.06 Million ≈ $56.97 Million |
CHF437.94 Million ≈ $553.68 Million |
-0.94pp |
| 2014-12-31 | 11.23% | CHF25.33 Million ≈ $32.02 Million |
CHF225.62 Million ≈ $285.25 Million |
-38.91pp |
| 2013-12-31 | 50.13% | CHF121.82 Million ≈ $154.02 Million |
CHF243.00 Million ≈ $307.22 Million |
+50.13pp |
| 2012-12-31 | 0.00% | CHF1.00 ≈ $1.26 |
CHF151.84 Million ≈ $191.97 Million |
-0.11pp |
| 2010-12-31 | 0.11% | CHF101.00K ≈ $127.69K |
CHF91.83 Million ≈ $116.09 Million |
-0.08pp |
| 2009-12-31 | 0.19% | CHF139.00K ≈ $175.73K |
CHF71.46 Million ≈ $90.35 Million |
-- |
About COSMO Pharmaceuticals SA
Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris;… Read more